Cellectis SA

French clinical stage biotechnology company headquartered in Paris with operations in New York and Raleigh, founded in 1999 and listed on Euronext Growth and Nasdaq. Pioneered gene editing with meganucleases and TALEN and develops allogeneic off the shelf CAR T cell therapies for haematological cancers and solid tumours, running its own manufacturing and analytical facilities in the United States and partnering with AstraZeneca and others on cell and gene therapy programmes.